Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from$6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate ...